Connor Iapoce

The systematic review and meta-analysis of 13 studies found no evidence to support the use of topical NSAIDs for the treatment of central serous chorioretinopathy.

The analysis of questionnaire responses in Sweden suggests the socioeconomic factor of low household income had a crucial impact on vision-related quality of life.

Biosimilar infliximab-dyyb proves successful in achieving and maintaining the control of non-infectious uveitis in the study cohort.

Artificial intelligence use is growing across medicine. From imaging to chatbots, ophthalmology is the center of one of these transformations.

For DME eyes that did not sufficiently respond to prior treatment, the intravitreal implant was associated with improvements in both visual and anatomic outcomes.

Announced by Iveric Bio, topline results from the phase 3 GATHER2 clinical trial indicate monthly avacincaptad pegol significantly slowed GA growth compared to sham at 24 months.

Patients were treated with fewer anti-VEGF injections in 2020 compared to the previous year, but these changes did not significantly impact BCVA outcomes.

A post hoc analysis of the PREVENT trial suggests quarterly ranibizumab did not appear to affect drusen volume, drusen area, or GA progression compared to sham.

The association between antibiotic exposure and increased odds of AMD persisted after adjustment for well-established risk factors for the disease.

Rates of visual acuity loss among patients with neovascular age-related macular degeneration did not vary significantly in pre‐versus post‐lockdown time periods.

Factors including a longer diabetes duration and lower eGFR were associated with suboptimal treatment response to aflibercept in patients with DME.

Faricimab shows improved visual and anatomic outcomes in eyes with nAMD previously treated with aflibercept or brolucizumab.

New phase 2 study findings link levosulpiride treatment for 8 weeks with improved visual and structural outcomes and no significant adverse side effects.

The analysis found any metformin use decreased the odds of developing dry AMD, particularly cumulative 2-year doses of 1 to 270 g and 271 to 600 g.

A posthoc analysis of the phase 3 HAWK and HARRIER trials shows brolucizumab outperforms aflibercept at reducing SHRM thickness in eyes with nAMD.

On September 12, 2023, the FDA announced it had issued warning letters to 8 companies, including CVS Health and Walgreens, for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law.

Results from a cross-sectional analysis of NHANES data found a short sleep duration was associated with an increased risk of early AMD.

New data suggest patients with nAMD on prior anti-VEGF therapy experienced improved visual acuity and macular OCT parameters after switching to faricimab.

Findings from two recent studies provide insight into the association between anti-VEGF treatment for retinal diseases and the risk of kidney injury.

Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and managing director of Opthea Limited, to discuss sozinibercept, a novel recombinant “trap” fusion protein targeting inhibition of VEGF-C and VEGF-D.

Results from a secondary analysis of PALADIN showed the 0.19-mg implant was associated with mostly stable IOPs in eyes with DME over a 36-month period.

Results from the 2-year retrospective cohort study showed patients with DME and extremely high or low eGFR had a greater decline in eGFR.

Analyses suggest users of calcium channel blockers had 39% higher odds of glaucoma compared with non-users, after controlling for confounders.

A treat-and-extend faricimab regimen may improve functional and anatomical outcomes at 1 year in patients with DME recalcitrant to aflibercept treatment.

The study evaluated 10-year outcomes of anti-VEGF therapy using a PRN treatment regimen for eyes with neovascular AMD in real-world clinical practice.

An analysis of more than 4000 adolescents and young adults in the US found those who more recently used tobacco products reported more symptoms than other users.

An analysis of ophthalmology subspecialty fellowships in 2021 revealed a lower match rate for applicants considered underrepresented in medicine.

ORION-8 results showed the change in LDL-C from baseline in the 3-year open-label extension was similar to the change observed during 18 months of placebo-controlled comparison.

A secondary analysis of the DELIVER trial found dapagliflozin significantly reduced the full spectrum of worsening heart failure events, including outpatient oral diuretic intensification.